Nautilus Biotechnology (NAUT) Non-Current Deffered Revenue (2020 - 2021)
Nautilus Biotechnology's (NAUT) quarterly Non-Current Deffered Revenue came in at $5.2 million in Q1 2021, little changed quarter-over-quarter from $5.2 million in Q4 2020.
Nautilus Biotechnology (NAUT) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Nautilus Biotechnology has disclosed Non-Current Deffered Revenue across 2 years of filings, most recently posting $5.2 million for Q1 2021.
- Non-Current Deffered Revenue for Q1 2021 came in at $5.2 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2021 was $5.2 million (changed N/A YoY), and the FY2020 annual result was $5.2 million, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $5.2 million for Q1 2021 at Nautilus Biotechnology, roughly flat from $5.2 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $5.2 million in Q3 2020 to a low of $5.2 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Nautilus Biotechnology | 289.99 Mn | 194.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 5.23 Mn |
| Dec 31, 2020 | 5.23 Mn |
| Sep 30, 2020 | 5.23 Mn |